secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beta Bionics, Inc. (BBNX)
CIK:        0001674632
Form:       8-K
Filed at:   2025-07-29T23:59:59+00:00
Accession:  0001171843-25-004780
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beta Bionics Q2 net sales up 54% to $23.2M; raises full-year guidance
---------------------------------------------------------------------

- Net sales $23.2M (+54% YoY); DME channel $18.6M (+31%), PBP channel $4.6M (+498%).
- Installed base 24,085 users (+200%); new patient starts 4,934 (+57%), 71% from MDI.
- Net loss $16.9M (negative 73% of sales) vs $14.5M (negative 96%) in Q2 2024.
- Adjusted EBITDA -$14.5M (negative 63% of sales) vs -$10.0M (negative 66%).
- Cash and investments $280.9M as of June 30; raised full-year 2025 revenue and adjusted EBITDA guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325004780/0001171843-25-004780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674632/000117184325004780/f8k_072925.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer